Hence, several TCP derivatives with an improved specificity for LSD1 have been developed, such as GSK2879552 and ORY‐1001, which are currently in phase 1 clinical trials for treating acute myeloid leukemia and SCLC (Mohammad et al., 2015; Stazi et al., 2016). The gene discussed is KDM1A; the disease is acute myeloid leukemia.